BRD4 and neoplasm: Anti–PD-L1 therapy did not reduce tumor volumes of BRD4 WT mice but was effective in mice deficient in BRD4 in the myeloid compartment (WT + anti–PD-L1 vs. cKO plus anti–PD-L1, P < 0.05) (Figure 7B).